SlideShare une entreprise Scribd logo
1  sur  72
#LOWER RESPIRATORY DISORDER
#CHRONIC RESPIRATORY DISORDER
DISORDER OF RESPIRATORY SYSTEM
INTRODUCTION
 Respiratory illness are common in children under 5
years of age. Most children will develop three to eight
episodes of cold or respiratory illnesses in a year.
 Most cases are mild about one-third of all
hospitalizations in this age group are due to
respiratory problems including asthma and
pneumonia.
Lower respiratory disorders
Including:
 Acute bronchitis
 Bronchiolitis
 Pneumonia
 Respiratory distress syndrome
Chronic respiratory disorders
Including:
 Tuberculosis
Asthma
Cystic fibrosis
Lung abscess
Lower respiratory disorders ACUTE
BRONCHITIS
ACUTE BRONCHITIS
DEFINITION
 Acute bronchitis is swelling and irritation in
child's air passages.
 This irritation may cause him to cough or
have other breathing problems.
 Acute bronchitis often starts because of
another illness, such as a cold or the flu.
The illness spreads from your child's nose
and throat to his windpipe and airways
 Acute bronchitis lasts about 2 weeks and is
usually not a serious illness
Incidence & etiology
 Acute bronchitis occure especially in
children less than 4 year of age. It is
usually associated with previous upper
respiratory infection.
 Acute bronchitis may be bacterial
(mycoplasma pneumoniae) or viral
(adenovirus, rhinovirus) in origin.
 Physical and chemical agent like dust,
allergens , strong fumes etc.
Clinical features
 Runny nose
 Malaise
 Chills
 Fever
 Back and muscle pain
 Sore thoroat
 Wheezing
 The symptoms usually last for 7-14 days
Diagnostic evaluation
History collection
Physical examination
Chest auscultation
Chest x-ray
Management
Administration of:
Antibiotics
Cough expectorant
Antipyretic
Steam inhalation
Bronchiolitis
Bronchiolitis
Definition
Bronchiolitis is a serious illness characterized by
inflammation of bronchioles, causing severe
dyspnea.
incidence & etiology:
 Brochiolitis is common in infants under the age of 6
months. It
Is common in winter and early spring.
 The exact etiology is not clear.
 The agent may be-
virus-adenovirus, influenza virus, respiratory syncytial
virus
bacteria- H.influenzae, pneumococcus, streptococcus
hemolyticus
CLINICAL FEATURES
 Dyspnea ( rapid shallow breathing )
 Mild to moderate fever
 Nasal flaring
 Cyanosis
 Runny nose
 Cough
 Wheezing
 Intercostal retraction
 Widespread crepitations
diagnostic evaluation
Chest x-ray
Viral test- collect a sample of
mucus
Blood test
Management
 Oxygen administration
 Maintaining atmosphere well
saturated with water vapour
 Mild sedation
 Postural drainage
 Iv fluid are given to combat
dehydration
 antibiotics
Pneumonia
Pneumonia
DEFINITION
 It is a inflammatory process
involving lung parenchyma.
 It is a inflammation with
consolidation (it is a state of being
solid with exudate) of parenchymal
cells of the lung.
INCIDENCE
 Occurs most commonly in infants and
young children
 30% children are admitted because of
pneumonia
 90% of deaths in respiratory illnesses are
due to pneumonia
CLASSIFICATION
On anatomical basis-
 Lobor or lobular pneumonia:one or more lobes of
lungs are involved
 Interstitial pneumonia: interstitial tissue of lungs are
affected
 Bronchopneumonia : patchy consolidation of lungs
is known as bronchiopneumonia
ON ETIOLOGIC BASIS-
 bacterial pneumonia: pneumococcus, strptococcus,
staphylococcus, H.influenzae and haemophilus
pertusis.
 Viral pneumonia: inmfluenza, ,measels, adenovirus,
respiratoy syncytial virus
 Fungal
pneumonia:histoplasmosis,coccidioidomycosis
 Protozoal pneumonia: pneumocystis
MISCELLANEOUS TYPES:
 Aspiration pneumonia: it is caused by
aspiration of food, nasal drop, amniotic
fluid by new born.
 Loffler pneumonia: eosinophils
accumulate in lungs in response to
parasitic infection.
 Hypersensitivity pneumonia: inflammation
of alveoli within the lungs caused by
hypersensitivity to inhaled dust.
 Hypostatic pneumonia: collection of fluid
in dorsal region of lungs .
Clinical features
 Fever with chills
 Cough with thick sputum
 Increased respiratory rate
 Nasal flaring
 Running nose
 Irritability
 Malaise
 Sore throat
 Anorexia
Late symptoms include:
 Convulsions
 Wheezing
 Hoarseness of voice
 cyanosis
Pathophysiology
Diagnostic evaluation
 History collection
 Chest x-ray
 Blood culture
 Isolation of organism from
nasopharynx by culture or PCR
 Blood test
Management
Medical management-
 ANTIBIOTICS;
penicillin,amoxicillin,erythromycin,
azithromycin ,clarithromycin
 ANTIPYRATICS
NURSING MANAGEMENT
 ASSESS AND MONITOR THE CHILD’S RESPIRATORY
RATE AND BREATH SOUND.
 CONTROL OF FEVER
 MAINTAINE PATENT AIRWAY
 PROVISION OF HIGH HUMIDIFIED OXYGEN.
 MONITOR RESPIRATORY STATUS AND VITAL SIGNS.
 ADMINISTRATION OF ANTIBIOTICS
 PROMOTION OF REST
 PROVISION OF APPROPRIATE AND ADEQUATE
FLUIDS AND NUTRITION
 SUPPORT AND EDUCATION TO PARENTS
 PREVENTION OF COMPLICATIONS
COMPLICATION
 Pleural effusion
 Emphysema
 Pneumatocele
 bronchiecasis
Prevention
Two vaccine are available to prevent
pneumococcal disease.
 Pneumococcal conjugate vaccine (PCV13)
 Pneumococcal polysaccharide
vaccine(PPSV23); pneumovax
Respiratory distress syndrome
Respiratory distress syndrome
Definition
• Respiratory Distress Syndrome (RDS) formerly
known as hyaline membrane disease, is a life
threatening lung disorder that results from
underdeveloped and small alveoli and insufficient
level of pulmonary surfactant that leads to
atelectasis.
• It is the leading cause of death in preterm infants
• Occurs in 50% babies born at26-28 weeks and
25% of babies born at 30-31 weeks
CAUSES
RDS occurs as a result of insufficient
production of surfactant which is seen
in:
 Prematurity (more common)
 Maternal diabetes (Inadequate
utilization of glycogen for surfactant
production)
 Meconium aspiration syndrome
Clinical features
 Tachypnea
 Tachycardia
 Chest wall retraction
 Expiratory grunting
 Nasal flaring
 cyanosis
Pathophysiology
Diagnostic evaluation
• Details of Antenatal and Prenatal History
• Assessment and Evaluation of Clinical manifestation
• Arterial Blood gas analysis:
 PCO2 above 65mmHg(normal:45mmhg)
 PO2 of 40mmHg(normal:50mmhg)
 pH below 7.15(normal7.35-7.45)
• X-ray shows alveolar atelectasis
• Pulse oximetry: Decreased SPO2
•Shake test
• Prenatal diagnosis of RDS can be made by determining
Lecithin/sphingomyelin ratio in amniotic fluid after 35
weeks of gestation.
Shake test
Management
 Neonate should be placed in Newborn Unit (NBU) and
nursed in warm incubator. The infant must be kept
warm (36.50C).
 Oxygen administration- Adequate, warm and
humidified O2 in high concentration is given through
plastic hood to maintain arterial PO2 between 50-
90mmHg is given.
 Ventilator support-Continuous Positive Airway
Pressure (CPAP) is indicated and useful in infant with
decreased lung compliance.
 Maintenance of nutrition and hydration by IV route.
 Maintenance of acid base balance
 Surfactant therapy- Via Endotracheal tube is indicated
in all neonates with RDS and prophylaxis can be given
in all premature infants. Adequate oxygenation,
Chronic respiratory disorders
INCLUDING;
 TUBERCULOSIS
 ASTHMA
 CYSTIC FIBROSIS
 LUNG ABSCESS
TUBERCULOSIS
TUBERCULOSIS
Definition
Tuberculosis is a chronic infectious disease
caused by Mycobacterium tuberculosis. Children
are susceptible to both human(mycobacterium
tuberculosis) and bovine(mycobacterium bovis)
organisms.
Prevalence
 TB is the 8th leading cause of death in
children between 1 and 4 year of age
 Children have a lower prevalence rate (5-
10%) as compared o adolescents(10-
35%) and adults(30-50%).
Epidemiology
 Agent : Mycobacterium tuberculosis, M. bovis
 Reservoir : Infected patient
 Mode of infection : Droplet infection, dust,
ingestion, skin, mucous membrane, skin
 Host Factors
 Age : all ages affected, congenital is rare
 Sex : Girls > boys at Puberty
 Malnutrition : more succeptible
 Intercurrent infections : eg measles, whooping
cough
 Environment : overcrowding, inadequate
Pathophysiology
Pathophysiology
1. Tuberculosis bacillus present in the lungs of infectious person (by
droplet inhalation)
2. Inhaled tubercle bacilli gets lodged in the pulmonary alveoli
3. Cause inflammation with hyperemia & congestion in lungs
4. Cells such as macrophages, histocytes appear in the area of
inflammation
phagocytosis begins
5. Pulmonary alveoli get filled with exudates comprising of fibrin,
leukocytes, phagocytes and tubercle bacilli
6. The central part of inflamed area is necrosed
7. Bacilli may enter the lymphatics and bloodstream and are carried to
different part of body
Clinical features
 Incubation period varies between 4 and 12 weeks.
 fever
 Malaise
 Weight loss
 Coughing
 Night sweats
 Anorexia
 Hemoptysis (rare)
 Respiratory rate change
 Poor expansion of lungs
 Diminished breath sound
 Anemia , weakness & weight loss
Diagnostic evaluation
 History of contact
 Mantoux test
 Chest x-ray
 BCG test
 Laboratory investigation
ELISA test to detect mycobacterium
antigen and IgG , IgM , IgA
antibodies
Sputum or laryngeal swab culture
Drugs
 1 st line anti-tuberculous drugs
 Isoniazid (INAH) 5 mg/kg/day H
 Rifampicin 10 mg/kg/day R
 Pyrazinamide 25 mg/kg/day Z
 Ethambutol 20 mg/kg/day E
 Streptomycin
 2 nd Line drugs
 Cycloserine,
 ethionamaide,
 PAS,
 kanamycin
 capreomycin
 Other drugs Eg. Quinolones, rifamycin, amikacin,
imipenem, ampicillin
Phases of Treatment
 Intensive Phase:
 Eliminate bacterial load
 Prevent emergence of drug resistant strains
 Atleast 3 Bactericidal Drugs used
 Continuation Phase:
 Continue and complete therapy
 Atleast 2 Bactericidal drugs used
 Steroids:
 Anti inflammatory effect – millary, peritonitis,
pericarditis
 TB meningitis RNTCP Treatment
Nursing management
 Proper nutritious diet
 Adequate res must be provided to
children
 Avoidence of infection
 Regular immunization
 Proper coughing and sneezing technique
by covering the mouth & nose
 BCG vaccination should be carried out
for all children at birth or within 3 months
of age
 Parents are explained about the need of
Bronchial asthma
Bronchial asthma
Definition
Asthma is a chronic inflammatory disease ,
characterized by airway obstruction, airway
inflammation and an increased responsiveness of
trachea and bronchi to various stimuli.
incidence
Most cases have origin in first 2 year of life. Peak
incidence is seen in 5-10 years of age. Boys
suffer twice as much as girls.
Etiology
Pathophysiology
Clinical features
 Severe dyspnea
 Bouts of cough
 Wheezing
 Cyanosis
 Sweating
 Restlessness
 Extreme fatigue
Diagnostic evaluation
 History collection
 Physical examination
 Pulmonary function test
 Blood examination
 Chest x-ray
 Allergy test
Management
 Medical management:
solbutam
ol
Nursing management
 Providing emotional support& education
 Administering adequate fluids
 Provide rest and comfort
 Evaluate resipratory status & facilitate
breathing
Cystic fibrosis
Cystic fibrosis
Definition
 Cystic fibrosis is an autosomal recessive disorder
that affects epithelial cells of the respiratory ,
gastrointestinal and reproductive tracts and leads
to abnormal exocrine gland secretion
 Cystic fibrosis is a disease passed down through
families that cause thick, sticky mucus to build up in
the lungs, digestive tract and other areas of the
body.
Clinical features
Diagnostic evaluation
 Sweat (chloride) test
 Genetic test- blood and cheek scraping
cell can tested for mutation in the
CFTR(cystic fibrosis transmembrane
conductance regulator)<cell protein>
 Chest x-ray
 PFT
 Sputum culture
 Stool evaluation- tested for fat absorption
Management
 At present there is no cure for CF.
Treatment may include;
Chest physiotherapy
Exercise
Medications(bronchodialators, anti inflamatory
drugs)
Antibiotics
Management;
Appropriate diet
Vitamin supplements
Psychological support
Newer therapies include lung transplantation
Lung abscess
Lung abscess
Definition
 A localized area of destruction of lung
parenchyma in which infection by pyogenic
organisms results in tissue necrosis &
suppuration .
Types
 Primary abscess: it occurs in previously
normal lungs and may follow aspiration.
 Secondary abscess: it occurs in patient
with an underlying lung abnormality.
Clinical features
 Cough
 Fever
 Dyspnea
 Chest pain
 Vomiting
 Sputum production
 Weight loss
 Hemoptysis
 Decrease breath sound
 Tachypnea
 Crackles
Diagnostic evaluation
 History collection
 Physical examination
 Chest x-ray
 CT scan
 Sputum culture
 Pleural fluid and blood culture
 Bronchoscopy
Complication
 Brain abscess
 Empyema
 Pneumatocele
 Bronchopleural fistula
 bronchiectasis
Management
 IV antibiotics are given usually for about 2-
3 weeks.
 Perform surgery( lobectomy,
pneumonectomy)
 Supportive measures include:
Analgesics
Oxygen , if required
Rehydration , if indicated
Postural drainage with chest physiotherapy
Lower & chronic respiratory disease in children

Contenu connexe

Tendances (20)

Oxygen therapy
Oxygen therapyOxygen therapy
Oxygen therapy
 
Lower respiratory tract infection: BRONCHITIS, BRONCHIOLITIS, PNEUMONIA IN CH...
Lower respiratory tract infection: BRONCHITIS, BRONCHIOLITIS, PNEUMONIA IN CH...Lower respiratory tract infection: BRONCHITIS, BRONCHIOLITIS, PNEUMONIA IN CH...
Lower respiratory tract infection: BRONCHITIS, BRONCHIOLITIS, PNEUMONIA IN CH...
 
Oxygen delivery devices
Oxygen delivery devicesOxygen delivery devices
Oxygen delivery devices
 
oxygen therapy
oxygen therapyoxygen therapy
oxygen therapy
 
Tracheostomy
Tracheostomy Tracheostomy
Tracheostomy
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Oxygen therapy -
Oxygen therapy - Oxygen therapy -
Oxygen therapy -
 
Oxygen therapy in pediatrics
Oxygen therapy in pediatricsOxygen therapy in pediatrics
Oxygen therapy in pediatrics
 
Anatomy and physiology of lung
Anatomy and physiology of lungAnatomy and physiology of lung
Anatomy and physiology of lung
 
Foreign body aspiration 10 12-19
Foreign body aspiration 10 12-19Foreign body aspiration 10 12-19
Foreign body aspiration 10 12-19
 
nursing care on pulmonary edema
nursing care on pulmonary edemanursing care on pulmonary edema
nursing care on pulmonary edema
 
Atelectasis- Easy explanation
Atelectasis- Easy explanationAtelectasis- Easy explanation
Atelectasis- Easy explanation
 
Oxygen therapy
Oxygen therapyOxygen therapy
Oxygen therapy
 
Copd ppt
Copd pptCopd ppt
Copd ppt
 
Acute respiratory failure ppt
Acute respiratory failure pptAcute respiratory failure ppt
Acute respiratory failure ppt
 
Infection control protocol in icu
Infection control protocol in icuInfection control protocol in icu
Infection control protocol in icu
 
Oxygen therapy in pediatrics
Oxygen therapy in pediatricsOxygen therapy in pediatrics
Oxygen therapy in pediatrics
 
Oxygen therapy
Oxygen therapyOxygen therapy
Oxygen therapy
 
Oxygen therapy
Oxygen therapyOxygen therapy
Oxygen therapy
 
Introduction of bronchitis
Introduction of bronchitisIntroduction of bronchitis
Introduction of bronchitis
 

Similaire à Lower & chronic respiratory disease in children

Lower respiratory tract infection (LRTI) in
Lower respiratory tract infection (LRTI) inLower respiratory tract infection (LRTI) in
Lower respiratory tract infection (LRTI) inOsama Felemban
 
Rsv bronchiolitis ppt
Rsv bronchiolitis pptRsv bronchiolitis ppt
Rsv bronchiolitis pptPediatrics
 
Pediatric pneumonia.pptx
Pediatric pneumonia.pptxPediatric pneumonia.pptx
Pediatric pneumonia.pptxDrHananTork
 
Paediatric respiratory problems
Paediatric respiratory problemsPaediatric respiratory problems
Paediatric respiratory problemsmedicostest
 
Acute respiratory Infection & IMNCI
Acute respiratory Infection & IMNCIAcute respiratory Infection & IMNCI
Acute respiratory Infection & IMNCIRishabh Nahar
 
Pneumonia - Copy.ppt
Pneumonia - Copy.pptPneumonia - Copy.ppt
Pneumonia - Copy.pptAmareDejene
 
Acute Bronchiolitis and Viral pneumonia.pptx
Acute Bronchiolitis and Viral pneumonia.pptxAcute Bronchiolitis and Viral pneumonia.pptx
Acute Bronchiolitis and Viral pneumonia.pptxDr Debasish Mohapatra
 
Community acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenCommunity acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenHardik Shah
 
Pneumonia, causes, risk factors, treatment.pdf
Pneumonia, causes, risk factors, treatment.pdfPneumonia, causes, risk factors, treatment.pdf
Pneumonia, causes, risk factors, treatment.pdfLankeSuneetha
 
Pneumonia in children by shivam
Pneumonia in children by shivamPneumonia in children by shivam
Pneumonia in children by shivamShivam Gautam
 
Bronchiolitis & Nursing care
Bronchiolitis & Nursing careBronchiolitis & Nursing care
Bronchiolitis & Nursing careV4Veeru25
 
approachtorecurrentpneumonia-170523181837.pdf
approachtorecurrentpneumonia-170523181837.pdfapproachtorecurrentpneumonia-170523181837.pdf
approachtorecurrentpneumonia-170523181837.pdfSatyajitNaskar4
 

Similaire à Lower & chronic respiratory disease in children (20)

Bronchopneumonia
BronchopneumoniaBronchopneumonia
Bronchopneumonia
 
Lower respiratory tract infection (LRTI) in
Lower respiratory tract infection (LRTI) inLower respiratory tract infection (LRTI) in
Lower respiratory tract infection (LRTI) in
 
Rsv bronchiolitis ppt
Rsv bronchiolitis pptRsv bronchiolitis ppt
Rsv bronchiolitis ppt
 
Croup syndrome.pptx
Croup syndrome.pptxCroup syndrome.pptx
Croup syndrome.pptx
 
pneumonia.pptx
pneumonia.pptxpneumonia.pptx
pneumonia.pptx
 
Pediatric pneumonia.pptx
Pediatric pneumonia.pptxPediatric pneumonia.pptx
Pediatric pneumonia.pptx
 
Paediatric respiratory problems
Paediatric respiratory problemsPaediatric respiratory problems
Paediatric respiratory problems
 
Bela
BelaBela
Bela
 
Acute respiratory Infection & IMNCI
Acute respiratory Infection & IMNCIAcute respiratory Infection & IMNCI
Acute respiratory Infection & IMNCI
 
Pneumonia - Copy.ppt
Pneumonia - Copy.pptPneumonia - Copy.ppt
Pneumonia - Copy.ppt
 
Acute Bronchiolitis and Viral pneumonia.pptx
Acute Bronchiolitis and Viral pneumonia.pptxAcute Bronchiolitis and Viral pneumonia.pptx
Acute Bronchiolitis and Viral pneumonia.pptx
 
pneumonia.pptx
pneumonia.pptxpneumonia.pptx
pneumonia.pptx
 
Community acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in childrenCommunity acquired pneumonia [cap] in children
Community acquired pneumonia [cap] in children
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Pneumonia, causes, risk factors, treatment.pdf
Pneumonia, causes, risk factors, treatment.pdfPneumonia, causes, risk factors, treatment.pdf
Pneumonia, causes, risk factors, treatment.pdf
 
Pneumonia in children by shivam
Pneumonia in children by shivamPneumonia in children by shivam
Pneumonia in children by shivam
 
Bronchiolitis
BronchiolitisBronchiolitis
Bronchiolitis
 
Bronchiolitis & Nursing care
Bronchiolitis & Nursing careBronchiolitis & Nursing care
Bronchiolitis & Nursing care
 
Pneumonia
Pneumonia Pneumonia
Pneumonia
 
approachtorecurrentpneumonia-170523181837.pdf
approachtorecurrentpneumonia-170523181837.pdfapproachtorecurrentpneumonia-170523181837.pdf
approachtorecurrentpneumonia-170523181837.pdf
 

Dernier

On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxnegromaestrong
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfChris Hunter
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docxPoojaSen20
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfAyushMahapatra5
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docxPoojaSen20
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIShubhangi Sonawane
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Shubhangi Sonawane
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDThiyagu K
 

Dernier (20)

On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
psychiatric nursing HISTORY COLLECTION .docx
psychiatric  nursing HISTORY  COLLECTION  .docxpsychiatric  nursing HISTORY  COLLECTION  .docx
psychiatric nursing HISTORY COLLECTION .docx
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
PROCESS RECORDING FORMAT.docx
PROCESS      RECORDING        FORMAT.docxPROCESS      RECORDING        FORMAT.docx
PROCESS RECORDING FORMAT.docx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-IIFood Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
Food Chain and Food Web (Ecosystem) EVS, B. Pharmacy 1st Year, Sem-II
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
Ecological Succession. ( ECOSYSTEM, B. Pharmacy, 1st Year, Sem-II, Environmen...
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 

Lower & chronic respiratory disease in children

  • 1. #LOWER RESPIRATORY DISORDER #CHRONIC RESPIRATORY DISORDER DISORDER OF RESPIRATORY SYSTEM
  • 2. INTRODUCTION  Respiratory illness are common in children under 5 years of age. Most children will develop three to eight episodes of cold or respiratory illnesses in a year.  Most cases are mild about one-third of all hospitalizations in this age group are due to respiratory problems including asthma and pneumonia.
  • 3. Lower respiratory disorders Including:  Acute bronchitis  Bronchiolitis  Pneumonia  Respiratory distress syndrome
  • 4. Chronic respiratory disorders Including:  Tuberculosis Asthma Cystic fibrosis Lung abscess
  • 5. Lower respiratory disorders ACUTE BRONCHITIS
  • 6. ACUTE BRONCHITIS DEFINITION  Acute bronchitis is swelling and irritation in child's air passages.  This irritation may cause him to cough or have other breathing problems.  Acute bronchitis often starts because of another illness, such as a cold or the flu. The illness spreads from your child's nose and throat to his windpipe and airways  Acute bronchitis lasts about 2 weeks and is usually not a serious illness
  • 7. Incidence & etiology  Acute bronchitis occure especially in children less than 4 year of age. It is usually associated with previous upper respiratory infection.  Acute bronchitis may be bacterial (mycoplasma pneumoniae) or viral (adenovirus, rhinovirus) in origin.  Physical and chemical agent like dust, allergens , strong fumes etc.
  • 8. Clinical features  Runny nose  Malaise  Chills  Fever  Back and muscle pain  Sore thoroat  Wheezing  The symptoms usually last for 7-14 days
  • 9. Diagnostic evaluation History collection Physical examination Chest auscultation Chest x-ray
  • 12. Bronchiolitis Definition Bronchiolitis is a serious illness characterized by inflammation of bronchioles, causing severe dyspnea. incidence & etiology:  Brochiolitis is common in infants under the age of 6 months. It Is common in winter and early spring.  The exact etiology is not clear.  The agent may be- virus-adenovirus, influenza virus, respiratory syncytial virus bacteria- H.influenzae, pneumococcus, streptococcus hemolyticus
  • 13. CLINICAL FEATURES  Dyspnea ( rapid shallow breathing )  Mild to moderate fever  Nasal flaring  Cyanosis  Runny nose  Cough  Wheezing  Intercostal retraction  Widespread crepitations
  • 14. diagnostic evaluation Chest x-ray Viral test- collect a sample of mucus Blood test
  • 15. Management  Oxygen administration  Maintaining atmosphere well saturated with water vapour  Mild sedation  Postural drainage  Iv fluid are given to combat dehydration  antibiotics
  • 17. Pneumonia DEFINITION  It is a inflammatory process involving lung parenchyma.  It is a inflammation with consolidation (it is a state of being solid with exudate) of parenchymal cells of the lung.
  • 18. INCIDENCE  Occurs most commonly in infants and young children  30% children are admitted because of pneumonia  90% of deaths in respiratory illnesses are due to pneumonia
  • 19. CLASSIFICATION On anatomical basis-  Lobor or lobular pneumonia:one or more lobes of lungs are involved  Interstitial pneumonia: interstitial tissue of lungs are affected  Bronchopneumonia : patchy consolidation of lungs is known as bronchiopneumonia ON ETIOLOGIC BASIS-  bacterial pneumonia: pneumococcus, strptococcus, staphylococcus, H.influenzae and haemophilus pertusis.  Viral pneumonia: inmfluenza, ,measels, adenovirus, respiratoy syncytial virus  Fungal pneumonia:histoplasmosis,coccidioidomycosis  Protozoal pneumonia: pneumocystis
  • 20. MISCELLANEOUS TYPES:  Aspiration pneumonia: it is caused by aspiration of food, nasal drop, amniotic fluid by new born.  Loffler pneumonia: eosinophils accumulate in lungs in response to parasitic infection.  Hypersensitivity pneumonia: inflammation of alveoli within the lungs caused by hypersensitivity to inhaled dust.  Hypostatic pneumonia: collection of fluid in dorsal region of lungs .
  • 21. Clinical features  Fever with chills  Cough with thick sputum  Increased respiratory rate  Nasal flaring  Running nose  Irritability  Malaise  Sore throat  Anorexia Late symptoms include:  Convulsions  Wheezing  Hoarseness of voice  cyanosis
  • 23. Diagnostic evaluation  History collection  Chest x-ray  Blood culture  Isolation of organism from nasopharynx by culture or PCR  Blood test
  • 25. NURSING MANAGEMENT  ASSESS AND MONITOR THE CHILD’S RESPIRATORY RATE AND BREATH SOUND.  CONTROL OF FEVER  MAINTAINE PATENT AIRWAY  PROVISION OF HIGH HUMIDIFIED OXYGEN.  MONITOR RESPIRATORY STATUS AND VITAL SIGNS.  ADMINISTRATION OF ANTIBIOTICS  PROMOTION OF REST  PROVISION OF APPROPRIATE AND ADEQUATE FLUIDS AND NUTRITION  SUPPORT AND EDUCATION TO PARENTS  PREVENTION OF COMPLICATIONS
  • 26. COMPLICATION  Pleural effusion  Emphysema  Pneumatocele  bronchiecasis
  • 27. Prevention Two vaccine are available to prevent pneumococcal disease.  Pneumococcal conjugate vaccine (PCV13)  Pneumococcal polysaccharide vaccine(PPSV23); pneumovax
  • 29. Respiratory distress syndrome Definition • Respiratory Distress Syndrome (RDS) formerly known as hyaline membrane disease, is a life threatening lung disorder that results from underdeveloped and small alveoli and insufficient level of pulmonary surfactant that leads to atelectasis. • It is the leading cause of death in preterm infants • Occurs in 50% babies born at26-28 weeks and 25% of babies born at 30-31 weeks
  • 30.
  • 31. CAUSES RDS occurs as a result of insufficient production of surfactant which is seen in:  Prematurity (more common)  Maternal diabetes (Inadequate utilization of glycogen for surfactant production)  Meconium aspiration syndrome
  • 32. Clinical features  Tachypnea  Tachycardia  Chest wall retraction  Expiratory grunting  Nasal flaring  cyanosis
  • 34. Diagnostic evaluation • Details of Antenatal and Prenatal History • Assessment and Evaluation of Clinical manifestation • Arterial Blood gas analysis:  PCO2 above 65mmHg(normal:45mmhg)  PO2 of 40mmHg(normal:50mmhg)  pH below 7.15(normal7.35-7.45) • X-ray shows alveolar atelectasis • Pulse oximetry: Decreased SPO2 •Shake test • Prenatal diagnosis of RDS can be made by determining Lecithin/sphingomyelin ratio in amniotic fluid after 35 weeks of gestation.
  • 36. Management  Neonate should be placed in Newborn Unit (NBU) and nursed in warm incubator. The infant must be kept warm (36.50C).  Oxygen administration- Adequate, warm and humidified O2 in high concentration is given through plastic hood to maintain arterial PO2 between 50- 90mmHg is given.  Ventilator support-Continuous Positive Airway Pressure (CPAP) is indicated and useful in infant with decreased lung compliance.  Maintenance of nutrition and hydration by IV route.  Maintenance of acid base balance  Surfactant therapy- Via Endotracheal tube is indicated in all neonates with RDS and prophylaxis can be given in all premature infants. Adequate oxygenation,
  • 37. Chronic respiratory disorders INCLUDING;  TUBERCULOSIS  ASTHMA  CYSTIC FIBROSIS  LUNG ABSCESS
  • 39. TUBERCULOSIS Definition Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. Children are susceptible to both human(mycobacterium tuberculosis) and bovine(mycobacterium bovis) organisms.
  • 40. Prevalence  TB is the 8th leading cause of death in children between 1 and 4 year of age  Children have a lower prevalence rate (5- 10%) as compared o adolescents(10- 35%) and adults(30-50%).
  • 41. Epidemiology  Agent : Mycobacterium tuberculosis, M. bovis  Reservoir : Infected patient  Mode of infection : Droplet infection, dust, ingestion, skin, mucous membrane, skin  Host Factors  Age : all ages affected, congenital is rare  Sex : Girls > boys at Puberty  Malnutrition : more succeptible  Intercurrent infections : eg measles, whooping cough  Environment : overcrowding, inadequate
  • 42. Pathophysiology Pathophysiology 1. Tuberculosis bacillus present in the lungs of infectious person (by droplet inhalation) 2. Inhaled tubercle bacilli gets lodged in the pulmonary alveoli 3. Cause inflammation with hyperemia & congestion in lungs 4. Cells such as macrophages, histocytes appear in the area of inflammation phagocytosis begins 5. Pulmonary alveoli get filled with exudates comprising of fibrin, leukocytes, phagocytes and tubercle bacilli 6. The central part of inflamed area is necrosed 7. Bacilli may enter the lymphatics and bloodstream and are carried to different part of body
  • 43. Clinical features  Incubation period varies between 4 and 12 weeks.  fever  Malaise  Weight loss  Coughing  Night sweats  Anorexia  Hemoptysis (rare)  Respiratory rate change  Poor expansion of lungs  Diminished breath sound  Anemia , weakness & weight loss
  • 44. Diagnostic evaluation  History of contact  Mantoux test  Chest x-ray  BCG test  Laboratory investigation ELISA test to detect mycobacterium antigen and IgG , IgM , IgA antibodies Sputum or laryngeal swab culture
  • 45. Drugs  1 st line anti-tuberculous drugs  Isoniazid (INAH) 5 mg/kg/day H  Rifampicin 10 mg/kg/day R  Pyrazinamide 25 mg/kg/day Z  Ethambutol 20 mg/kg/day E  Streptomycin  2 nd Line drugs  Cycloserine,  ethionamaide,  PAS,  kanamycin  capreomycin  Other drugs Eg. Quinolones, rifamycin, amikacin, imipenem, ampicillin
  • 46. Phases of Treatment  Intensive Phase:  Eliminate bacterial load  Prevent emergence of drug resistant strains  Atleast 3 Bactericidal Drugs used  Continuation Phase:  Continue and complete therapy  Atleast 2 Bactericidal drugs used  Steroids:  Anti inflammatory effect – millary, peritonitis, pericarditis  TB meningitis RNTCP Treatment
  • 47. Nursing management  Proper nutritious diet  Adequate res must be provided to children  Avoidence of infection  Regular immunization  Proper coughing and sneezing technique by covering the mouth & nose  BCG vaccination should be carried out for all children at birth or within 3 months of age  Parents are explained about the need of
  • 49. Bronchial asthma Definition Asthma is a chronic inflammatory disease , characterized by airway obstruction, airway inflammation and an increased responsiveness of trachea and bronchi to various stimuli. incidence Most cases have origin in first 2 year of life. Peak incidence is seen in 5-10 years of age. Boys suffer twice as much as girls.
  • 51.
  • 52.
  • 54. Clinical features  Severe dyspnea  Bouts of cough  Wheezing  Cyanosis  Sweating  Restlessness  Extreme fatigue
  • 55. Diagnostic evaluation  History collection  Physical examination  Pulmonary function test  Blood examination  Chest x-ray  Allergy test
  • 57. Nursing management  Providing emotional support& education  Administering adequate fluids  Provide rest and comfort  Evaluate resipratory status & facilitate breathing
  • 59. Cystic fibrosis Definition  Cystic fibrosis is an autosomal recessive disorder that affects epithelial cells of the respiratory , gastrointestinal and reproductive tracts and leads to abnormal exocrine gland secretion  Cystic fibrosis is a disease passed down through families that cause thick, sticky mucus to build up in the lungs, digestive tract and other areas of the body.
  • 61.
  • 62. Diagnostic evaluation  Sweat (chloride) test  Genetic test- blood and cheek scraping cell can tested for mutation in the CFTR(cystic fibrosis transmembrane conductance regulator)<cell protein>  Chest x-ray  PFT  Sputum culture  Stool evaluation- tested for fat absorption
  • 63. Management  At present there is no cure for CF. Treatment may include; Chest physiotherapy Exercise Medications(bronchodialators, anti inflamatory drugs) Antibiotics Management; Appropriate diet Vitamin supplements Psychological support Newer therapies include lung transplantation
  • 65. Lung abscess Definition  A localized area of destruction of lung parenchyma in which infection by pyogenic organisms results in tissue necrosis & suppuration .
  • 66.
  • 67. Types  Primary abscess: it occurs in previously normal lungs and may follow aspiration.  Secondary abscess: it occurs in patient with an underlying lung abnormality.
  • 68. Clinical features  Cough  Fever  Dyspnea  Chest pain  Vomiting  Sputum production  Weight loss  Hemoptysis  Decrease breath sound  Tachypnea  Crackles
  • 69. Diagnostic evaluation  History collection  Physical examination  Chest x-ray  CT scan  Sputum culture  Pleural fluid and blood culture  Bronchoscopy
  • 70. Complication  Brain abscess  Empyema  Pneumatocele  Bronchopleural fistula  bronchiectasis
  • 71. Management  IV antibiotics are given usually for about 2- 3 weeks.  Perform surgery( lobectomy, pneumonectomy)  Supportive measures include: Analgesics Oxygen , if required Rehydration , if indicated Postural drainage with chest physiotherapy